
ABVC
ABVC Biopharma Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.125
Open
3.100
VWAP
3.02
Vol
51.59K
Mkt Cap
71.57M
Low
3.000
Amount
155.85K
EV/EBITDA(TTM)
--
Total Shares
12.05M
EV
75.89M
EV/OCF(TTM)
--
P/S(TTM)
114.45
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2023Q4
0.00
-100%
--
--
Estimates Revision
Stock Price
Go Up

+155.46%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for ABVC Biopharma Inc (ABVC.O) is -0.62, compared to its 5-year average forward P/E of -5.87. For a more detailed relative valuation and DCF analysis to assess ABVC Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.87
Current PE
-0.62
Overvalued PE
1.81
Undervalued PE
-13.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
130.15
Current PS
17.11
Overvalued PS
416.65
Undervalued PS
-156.35
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
+166.83%
-2.29M
Operating Profit
FY2025Q2
YoY :
+122.72%
-2.33M
Net Income after Tax
FY2025Q2
YoY :
+62.50%
-0.13
EPS - Diluted
FY2025Q2
-894.17K
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ABVC News & Events
Events Timeline
2024-12-11 (ET)
2024-12-11
05:37:58
ABVC BioPharma receives $200,000 cash payment from OncoX

2024-11-14 (ET)
2024-11-14
08:03:15
ABVC BioPharma reports Q3 EPS (2c) vs (82c) last year

2024-10-22 (ET)
2024-10-22
08:48:07
ABVC BioPharma receives $50,000 in incremental licensing fees

Sign Up For More Events
Sign Up For More Events
News
9.5
08-14NASDAQ.COMAbvc BioPharma Doubles Assets in Q2
9.0
2024-12-19NewsfilterABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
7.5
2024-12-11NewsfilterABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
Sign Up For More News
People Also Watch

RKDA
Arcadia Biosciences Inc
4.350
USD
-0.68%

HOLO
MicroCloud Hologram Inc
4.420
USD
+0.45%

BGLC
BioNexus Gene Lab Corp
5.720
USD
+7.32%

EFOI
Energy Focus Inc
2.760
USD
+12.20%

BLMZ
Harrison Global Holdings Inc
0.185
USD
-2.63%

TGL
Treasure Global Inc
1.270
USD
-0.78%

FTFT
Future Fintech Group Inc
1.980
USD
+9.39%

PSTV
Plus Therapeutics Inc
0.483
USD
-0.21%

ATXG
Addentax Group Corp
0.479
USD
-0.21%
FAQ

What is ABVC Biopharma Inc (ABVC) stock price today?
The current price of ABVC is 3.04 USD — it has decreased -1.62 % in the last trading day.

What is ABVC Biopharma Inc (ABVC)'s business?

What is the price predicton of ABVC Stock?

What is ABVC Biopharma Inc (ABVC)'s revenue for the last quarter?

What is ABVC Biopharma Inc (ABVC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for ABVC Biopharma Inc (ABVC)'s fundamentals?

How many employees does ABVC Biopharma Inc (ABVC). have?
